Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097219 | 1.00 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL1995664 | 1.00 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL1532151 | 1.00 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL1995660 | 1.00 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL16817867 | 0.83 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL16817902 | 0.83 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL16817909 | 0.83 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL2244738 | 0.83 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL1468681 | 0.82 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL1468682 | 0.82 | SLC6A1 (0.33) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011029043-A1 | HETEROARYL BTK INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | ABBOTT LABORATORIES (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | SLC6A1 1291/4885SLC6A11 1767/4885SLC6A13 1262/4885 |
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | GRIN3A, GAP43, GRIN3B | SLC6A1 112/4885SLC6A11 99/4885SLC6A13 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.